How Is Graft-versus-Host Disease Classified?
Overview: GVHD is an immune-related complication of allo-HSCT in which donor immune cells may damage recipient tissues, including the skin, intestines, and liver. Clinicians generally distinguish acute GVHD (aGVHD) from chronic GVHD (cGVHD), considering timing, clinical features, and patterns of organ involvement. The two types differ in presentation and management. Understanding these distinctions helps patients recognize changes and participate in follow-up care.
Why does GVHD need to be classified?
Not all GVHD is the same. Its onset, immune features, and affected organs vary. Classification helps clinicians understand the pattern of disease and choose appropriate treatment. Acute and chronic GVHD are the two principal clinical categories.
What is acute GVHD?
Acute GVHD often develops relatively early after allo-HSCT. Traditionally, GVHD occurring within the first 100 days was called acute GVHD. It is caused by donor-derived immune cells attacking recipient tissues and most commonly involves the skin, intestines, and liver.
Acute GVHD affecting the skin
Skin is one of the most common sites of acute GVHD. Patients may develop a rash, redness, or itching; severe involvement can cause peeling or shedding of skin. Any new skin changes after transplant should be reported so the transplant team can determine whether GVHD is responsible.
Acute GVHD affecting the intestines
Intestinal involvement may cause diarrhea, abdominal pain, nausea, or vomiting; severe cases may include blood in the stool. Prompt assessment matters because ongoing intestinal injury can impair nutrition and increase infection risk.
Acute GVHD affecting the liver
Liver involvement may cause no obvious symptoms. Instead, blood tests may reveal increased bilirubin or other abnormal liver-function results. This is one reason routine post-transplant testing is important.
What is chronic GVHD?
Chronic GVHD usually appears later after transplantation. Compared with acute GVHD, the immune injury can be more complex and the symptoms more varied. It may affect the skin, mouth, eyes, lungs, gastrointestinal tract, liver, muscles, and joints. Some manifestations resemble autoimmune disorders, such as skin thickening or tightening and dry eyes or mouth.
How do acute and chronic GVHD differ?
Acute GVHD more commonly occurs early and primarily affects the skin, intestines, and liver. Chronic GVHD generally appears later, can affect a broader range of organs, and may have more complex symptoms. However, modern classification does not rely on time alone: chronic-type features can appear earlier, and some patients have overlapping acute and chronic manifestations. Doctors consider symptoms and test results together.
How is GVHD severity assessed?
In addition to determining whether GVHD is acute or chronic, clinicians assess its severity. This depends on which organs are involved, how extensive the damage is, how severe the symptoms are, and the patient’s overall condition. Mild skin involvement and severe intestinal GVHD can have very different consequences. Accurate assessment guides treatment selection.
Why does classification matter for treatment?
Acute GVHD management commonly focuses on controlling abnormal inflammation, limiting organ damage, and preventing infection. Chronic GVHD often requires longer-term, organ-specific care, tailored to severity and symptoms. Identifying the type and extent of GVHD is therefore an important step in treatment planning.
Summary
GVHD is broadly divided into acute and chronic forms. Acute disease commonly affects the skin, intestines, and liver early after transplant, while chronic disease often occurs later and may affect many systems. Accurate classification and severity assessment support appropriate treatment; regular follow-up helps identify changes early.